Pharvaris NV
NASDAQ:PHVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharvaris NV
Cash from Investing Activities
Pharvaris NV
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharvaris NV
NASDAQ:PHVS
|
Cash from Investing Activities
-€164.6k
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
Pharvaris NV
Glance View
Pharvaris NV is a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 34 full-time employees. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
See Also
What is Pharvaris NV's Cash from Investing Activities?
Cash from Investing Activities
-164.6k
EUR
Based on the financial report for Dec 31, 2025, Pharvaris NV's Cash from Investing Activities amounts to -164.6k EUR.
What is Pharvaris NV's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-33%
Over the last year, the Cash from Investing Activities growth was 69%. The average annual Cash from Investing Activities growth rates for Pharvaris NV have been -11% over the past three years , -33% over the past five years .
